Pralsetinib, sold under the brand name Gavreto, is a medication approved RET mutation-positive medullary thyroid cancer and RET fusion-positive differentiated thyroid cancer refractory to radioactive iodine therapy. Reference standards of Pralsetinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
Pralsetinib
Catalogue No.:PA 16 3770000
CAS :
Molecular Formula : C27H32FN9O2
Molecular Weight : 533.61
(S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethan-1-amine Hydrochloride
Catalogue No.:PA 16 3771000
Molecular Formula : C10H12ClFN4
Molecular Weight : 242.68
Methyl cis-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]cyclohexanecarboxylate
Catalogue No.:PA 16 3771001
Molecular Formula : C18H25N5O3
Molecular Weight : 359.43
cis-1-Methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]cyclohexanecarboxylic Acid
Catalogue No.:PA 16 3771002
Molecular Formula : C17H23N5O3
Molecular Weight : 345.4
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
